These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 17175982

  • 1. [Efficacy and safety of levofloxacin treatment of community--acquired pneumonia in hospitalized patients].
    Karwat KJ, Grabczak M, Chazan R.
    Pneumonol Alergol Pol; 2006; 74(1):77-9. PubMed ID: 17175982
    [Abstract] [Full Text] [Related]

  • 2. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
    Anzueto A, Niederman MS, Pearle J, Restrepo MI, Heyder A, Choudhri SH, Community-Acquired Pneumonia Recovery in the Elderly Study Group.
    Clin Infect Dis; 2006 Jan 01; 42(1):73-81. PubMed ID: 16323095
    [Abstract] [Full Text] [Related]

  • 3. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
    Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S, CAPRIE Study Group.
    Chest; 2005 Nov 01; 128(5):3398-406. PubMed ID: 16304291
    [Abstract] [Full Text] [Related]

  • 4. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.
    Curr Med Res Opin; 2008 Mar 01; 24(3):895-906. PubMed ID: 18419876
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
    Mokabberi R, Haftbaradaran A, Ravakhah K.
    J Clin Pharm Ther; 2010 Apr 01; 35(2):195-200. PubMed ID: 20456738
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X, Sikirica V, Schein JR, Grant R, Zarotsky V, Doshi D, Benson CJ, Riedel AA.
    Clin Ther; 2008 Feb 01; 30(2):358-71. PubMed ID: 18343274
    [Abstract] [Full Text] [Related]

  • 9. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors.
    Leroy O, Saux P, Bédos JP, Caulin E.
    Chest; 2005 Jul 01; 128(1):172-83. PubMed ID: 16002932
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
    Querol-Ribelles JM, Tenías JM, Querol-Borrás JM, Labrador T, Nieto A, González-Granda D, Martínez I.
    Int J Antimicrob Agents; 2005 Jan 01; 25(1):75-83. PubMed ID: 15620830
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
    Friedman H, Song X, Crespi S, Navaratnam P.
    Value Health; 2009 Jan 01; 12(8):1135-43. PubMed ID: 19695010
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
    Izadi M, Dadsetan B, Najafi Z, Jafari S, Mazaheri E, Dadras O, Heidari H, SeyedAlinaghi S, Voltarelli F.
    Recent Pat Antiinfect Drug Discov; 2018 Jan 01; 13(3):228-239. PubMed ID: 30360748
    [Abstract] [Full Text] [Related]

  • 17. High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study.
    Lee JH, Kim SW, Kim JH, Ryu YJ, Chang JH.
    Clin Drug Investig; 2012 Sep 01; 32(9):569-76. PubMed ID: 22765645
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens.
    Dunbar LM, Khashab MM, Kahn JB, Zadeikis N, Xiang JX, Tennenberg AM.
    Curr Med Res Opin; 2004 Apr 01; 20(4):555-63. PubMed ID: 15119993
    [Abstract] [Full Text] [Related]

  • 20. Oral levofloxacin in the treatment of community-acquired pneumonia.
    Nicodemo AC, Lima Nicodemo E, Idrahim KY.
    Braz J Infect Dis; 2000 Apr 01; 4(2):61-6. PubMed ID: 10795070
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.